Relmada Therapeutics (RLMD) Gross Profit (2012 - 2013)
Relmada Therapeutics (RLMD) posted quarterly Gross Profit of $164.0 for Q4 2013, down 45.15% year-over-year from $299.0 in Q4 2012, and down 47.44% quarter-over-quarter from $312.0 in Q2 2013.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Gross Profit (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Gross Profit for 2 consecutive years, with $164.0 the latest figure, recorded in Q4 2013.
- In Q4 2013, Gross Profit fell 45.15% year-over-year to $164.0; the TTM figure through Nov 2013 stood at $958.0 (changed N/A YoY), while the FY2013 annual figure was $1093.0, down 48.97% from the prior year.
- Gross Profit retreated to $164.0 in Q4 2013 per RLMD's latest filing, from $312.0 in the prior quarter.
- Across five years, Gross Profit topped out at $517.0 in Q3 2012 and bottomed at $108.0 in Q2 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Nov 30, 2013 | 164.00 |
| May 31, 2013 | 312.00 |
| Feb 28, 2013 | 482.00 |
| Nov 30, 2012 | 299.00 |
| Aug 31, 2012 | 517.00 |
| May 31, 2012 | 108.00 |